UCB-Tregs suppress pathogenic SLE cells, decrease CD19+B cells and monocytes, increase IL-10, and decrease IFN-γ, IP-10, TNF-α, IL-6, IL-17A, and sCD40L. This evidence concerns the gene CD19 and systemic lupus erythematosus.